Tempus AI reported Q2 2026 revenue of $382.5 million, a 22% year-over-year increase, driven by 31% growth in oncology volume and 36% growth in Data Licensing & Modeling. The company achieved GAAP net income of $5.6 million and Adjusted EBITDA of $8.0 million. It raised full-year 2026 revenue guidance to $1.595–$1.605 billion and expects ~$65 million in Adjusted EBITDA. Tempus completed a $460 million offering of convertible senior notes due 2032, signed approximately $200 million in new data licenses, and received FDA approval for its xT Tumor Only assay. Additionally, the company announced an agreement to acquire Personalis for ~$1.5 billion.

Tempus AI, Inc. entered into a Merger Agreement on July 20, 2026, to acquire Personalis, Inc. through a two-step merger involving its subsidiaries. The transaction consideration includes Tempus Class A Common Stock based on a variable exchange ratio determined by Tempus's stock price, with an option for Tempus to pay cash for up to 50% of the outstanding Personalis shares at $16.25 per share. Tempus AI, Inc. operates in the healthcare technology and data-driven precision medicine industry through its AI-driven platform.

Tempus AI, Inc. entered into a definitive agreement to acquire Personalis, Inc. for a total enterprise value of $1.5 billion. Personalis shareholders will receive $16.25 per share in a transaction structured as 100% stock, with Tempus having an option to elect up to 50% cash consideration. The deal is expected to close in late 2026 or early 2027 and is subject to shareholder and regulatory approvals. Tempus AI, Inc. is a technology company that uses artificial intelligence to advance precision medicine and patient care.